EMA urgently reviewing multiple sclerosis medicine Zinbryta following cases of inflammatory brain disorders
02/03/2018 Medicine to be voluntarily withdrawn from the market by the company The European Medicines Agency (EMA) has started an urgent review of the multiple sclerosis medicine Zinbryta (daclizumab) following 7 cases of serious inflammatory brain disorders in Germany, including … read more